Andiliy G. Lai

发表

A small molecule–kinase interaction map for clinical kinase inhibitors

L. Wodicka, D. Lockhart, P. Zarrinkar, 2005, Nature Biotechnology.

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Bioorganic & medicinal chemistry letters.

Mouse Models of Liver Fibrosis

Andiliy G. Lai, C. King, J. Hutchinson, 2016 .

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2019, Bioorganic & medicinal chemistry letters.

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Jilly F. Evans, Andiliy G. Lai, C. King, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, ACS medicinal chemistry letters.

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, Journal of medicinal chemistry.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Brian T. Campbell, Raffaella Faraoni, Andiliy G. Lai, 2011, Bioorganic & Medicinal Chemistry Letters.

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).

Jilly F. Evans, Andiliy G. Lai, D. Mackenna, 2017, Journal of medicinal chemistry.

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Jun Liang, A. Daemen, Andiliy G. Lai, 2018, Cancer Chemistry.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2009, Bioorganic & medicinal chemistry letters.